Daiichi Sankyo received federal approval for a label change to packaging for its Benicar drug to indicate that the medication may trigger spruelike enteropathy. "Health care professionals should tell patients to contact them if they develop severe, chronic diarrhea with substantial weight loss while taking an olmesartan-containing product, even if it takes months to years for symptoms to develop," an FDA MedWatch safety alert stated.

Related Summaries